Cidara Therapeutics, Inc. financial data

Symbol
CDTX on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
6310 Nancy Ridge Drive, Suite 101, San Diego, CA
State of incorporation
DE
Fiscal year end
December 31
Former names
K2 THERAPEUTICS, INC. (to 2/4/2015)
Latest financial report
10-Q - Q2 2024 - Aug 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 150 % +6.33%
Quick Ratio 8.19 %
Debt-to-equity 261 % -99.2%
Return On Equity -460 % +90.3%
Return On Assets -127 % -746%
Operating Margin -307 % -7622%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 7.04M shares -92.2%
Common Stock, Shares, Outstanding 4.57M shares -94.9%
Entity Public Float 100M USD +202%
Common Stock, Value, Issued 1K USD -88.9%
Weighted Average Number of Shares Outstanding, Basic 4.56M shares +1.29%
Weighted Average Number of Shares Outstanding, Diluted 4.56M shares +1.29%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 41.5M USD -49.5%
Revenue from Contract with Customer, Excluding Assessed Tax 2.83M USD
Research and Development Expense 59.3M USD -12.8%
General and Administrative Expense 14.6M USD -27.2%
Operating Income (Loss) -127M USD -3798%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -94.2M USD -1438%
Income Tax Expense (Benefit) 403K USD -100%
Net Income (Loss) Attributable to Parent -114M USD -1043%
Earnings Per Share, Basic -20.1 USD/shares -738%
Earnings Per Share, Diluted -20.1 USD/shares -738%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 164M USD +226%
Accounts Receivable, after Allowance for Credit Loss, Current 2.35M USD -57.2%
Inventory, Net 7.27M USD
Assets, Current 169M USD +169%
Property, Plant and Equipment, Net 602K USD +103%
Operating Lease, Right-of-Use Asset 3.32M USD -22.9%
Other Assets, Noncurrent 104K USD -90.2%
Assets 173M USD +154%
Accounts Payable, Current 2.29M USD +20.5%
Employee-related Liabilities, Current 3.51M USD -1.9%
Accrued Liabilities, Current 6.23M USD -37.9%
Liabilities, Current 39.6M USD -11.5%
Operating Lease, Liability, Noncurrent 2.33M USD -35.2%
Liabilities 42.4M USD -35.7%
Retained Earnings (Accumulated Deficit) -543M USD -26.5%
Stockholders' Equity Attributable to Parent 131M USD +5317%
Liabilities and Equity 173M USD +154%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -6.64M USD +39%
Net Cash Provided by (Used in) Financing Activities -93K USD -100%
Net Cash Provided by (Used in) Investing Activities -23K USD +75.5%
Common Stock, Shares Authorized 20M shares -90%
Common Stock, Shares, Issued 4.57M shares -94.9%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -6.76M USD -144%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 164M USD +226%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD -100%
Deferred Tax Assets, Valuation Allowance 83.1M USD +8.31%
Deferred Tax Assets, Gross 84.6M USD +9.64%
Operating Lease, Liability 3.6M USD -20.7%
Payments to Acquire Property, Plant, and Equipment 23K USD -75.5%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -114M USD -1043%
Lessee, Operating Lease, Liability, to be Paid 4.2M USD -25.6%
Property, Plant and Equipment, Gross 3.75M USD +10.9%
Operating Lease, Liability, Current 1.27M USD +47.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.73M USD +3.96%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.67M USD +4.06%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 595K USD -45.6%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.73M USD
Deferred Tax Assets, Operating Loss Carryforwards 35.5M USD -15.5%
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 11.5M USD +4.59%
Operating Lease, Payments 400K USD +33.3%
Deferred Tax Assets, Net of Valuation Allowance 1.5M USD +242%
Share-based Payment Arrangement, Expense 3.12M USD +5.9%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%